Epigenetic synergy between decitabine and platinum derivatives

BACKGROUND: Aberrant epigenetic silencing of tumor suppressor genes has been recognized as a driving force in cancer. Epigenetic drugs such as the DNA methylation inhibitor decitabine reactivate genes and are effective in myeloid leukemia, but resistance often develops and efficacy in solid tumors i...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Taichun, Si, Jiali, Raynal, Noël J-M, Wang, Xiaodan, Gharibyan, Vazganush, Ahmed, Saira, Hu, Xin, Jin, Chunlei, Lu, Yue, Shu, Jingmin, Estecio, Marcos RH, Jelinek, Jaroslav, Issa, Jean-Pierre J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567801/
https://www.ncbi.nlm.nih.gov/pubmed/26366234
http://dx.doi.org/10.1186/s13148-015-0131-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567801/
https://www.ncbi.nlm.nih.gov/pubmed/26366234
http://dx.doi.org/10.1186/s13148-015-0131-z

Ejemplares similares